INTRODUCTION AND OBJECTIVES: A multicenter, randomized, double-blind, placebo-controlled trial assessed efficacy and safety of ospemifene 60 mg QD in 631 postmenopausal women (age 40-80) with moderate to severe vaginal dryness as the most bothersome symptom (MBS) of VVA due to menopause. The primary aim was validation of vulvar photography as an objective measure of vulvar health. The secondary aim was to compare Vulvar Imaging Assessment Scale (VIAS) data from photographs to visual study measures assessed by investigators at each site, including Vaginal Health Index (VHI), and Vulvar Health Index (VuHI).
INTRODUCTION AND OBJECTIVES: Female sexual dysfunction (FSD) is associated with lower quality of life (QoL) in interstitial cystitis/bladder pain syndrome (IC/BPS). Our objectives were to: 1) compare the prevalence of FSD among IC/BPS, other non-urologic chronic pain conditions (positive controls, PCs) and healthy controls (HCs); 2) evaluate the role of psychosocial and urologic factors in FSD in all three cohorts; 3) correlate longitudinal changes in FSD with changes in IC/BPS symptoms.
METHODS Psychosocial factors such as depression, anxiety, personality traits, stress, and overall pain and urinary severity were shown to be associated with FSD in univariate analysis. Psychosocial factors, urinary and pain severity continued to be associated with FSD, after adjusting for age, spouse, ethnicity, number of genital sites with pain, and employment status (Table 1) . In IC/BPS pain or urinary symptoms did not correlate with changes in FSFI scores.
CONCLUSIONS: FSD is largely impacted by psychosocial risk factors and genital pain. Assessment of and targeting treatment to these risk factors may improve sexual function and QoL in IC/BPS. INTRODUCTION AND OBJECTIVES: CO 2 fractional laser (MonaLisa Touch) for treatment of vestibulodynia via a vestibular probe has been found clinically useful in a pilot study. A 3-site, prospective, double-blind, sham-controlled investigator-initiated research study was performed to further examine the safety and efficacy of CO 2 fractional laser delivery in women with vestibulodynia.
METHODS: Subjects meeting inclusion and exclusion criteria were randomized to active or sham treatment 2:1. Changes were assessed on multiple outcome measures, including cotton swab test at 1:00, 3:00, 5:00, 6:00, 7:00, 9:00 and 11:00 positions, Female Sexual Function Index (FSFI) pain domain and total score, Female Sexual Distress Score (FSDS-R), and O'Leary/Sant Voiding and Pain Indices (ICSI/ICPI). Each arm consisted of 3 treatments 4 weeks apart (weeks 0 e 8). Follow-up visits were completed at weeks 12 and 16. Subjects assigned to sham were crossed over to active treatment at 12 weeks, administered 3 active treatment sessions with additional follow-up.
RESULTS: This is an interim analysis of the first 53 subjects. Cotton swab test scores in subjects assigned to active treatment decreased at visits 3-6, whereas no laser therapy (sham arm) resulted in minimal changes. Change from baseline in cotton swab test scores was significantly reduced after active treatment at week 12 (mean [ 12 and 16 (mean [ 4.72; 95% CI [2.05, 7 .40] at both times). Distress related to vestibulodynia (change from baseline in FSDS-R scores) decreased significantly at weeks 12 and 16 (mean ], respectively). ICSI scores (change from baseline) decreased significantly at weeks 12 and 16 (mean [ -0.79 
